Geron Corporation Company Profile
NASDAQ: GERNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Geron at a glance
Geron Corporation (NASDAQ: GERN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Foster City, CA. Geron is led by Mr. Harout Semerjian and employs about 258 people. The company's shares have traded publicly since 1996.
At a market capitalization of $771.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0000886744, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Geron do?
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Business description based on the company's public filings.
Company information
- Legal name
- Geron Corporation
- Ticker
- NASDAQ: GERN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Harout Semerjian
- Employees
- 258
- Headquarters
- 919 East Hillsdale Boulevard, Foster City, CA, United States
- Phone
- 650 473 7700
- Website
- geron.com
- IPO year
- 1996
- Market cap
- $770.97M
- SEC CIK
- 0000886744
- Latest annual report
- 10-K · Mar 2, 2026
Companies similar to Geron
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMMXImmix Biopharma Inc. | 9.29 | -2.11% | $770.17M | vs GERN |
| LXRXLexicon Pharmaceuticals Inc. | 1.76 | 0.00% | $783.12M | vs GERN |
| HELPHelus Pharma Inc. | 10.72 | +2.00% | $783.21M | vs GERN |
| APMDApnimed Inc. | 18.22 | +1.00% | $758.51M | vs GERN |
| IVAInventiva S.A. American Depository Shares | 3.32 | -1.34% | $784.25M | vs GERN |
| OBXObsidian Therapeutics Inc. | 12.24 | -7.27% | $756.10M | vs GERN |
| AVTXAvalo Therapeutics Inc. | 13.43 | -1.10% | $720.25M | vs GERN |
| COLLCollegium Pharmaceutical Inc. | 22.11 | +0.82% | $719.80M | vs GERN |